RU2005136222A - Противоопухолевые комбинации - Google Patents
Противоопухолевые комбинации Download PDFInfo
- Publication number
- RU2005136222A RU2005136222A RU2005136222/14A RU2005136222A RU2005136222A RU 2005136222 A RU2005136222 A RU 2005136222A RU 2005136222/14 A RU2005136222/14 A RU 2005136222/14A RU 2005136222 A RU2005136222 A RU 2005136222A RU 2005136222 A RU2005136222 A RU 2005136222A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- interferon
- treatment
- neoplasms
- cci
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (15)
1. Применение CCI-779 и интерферона α для получения лекарственного средства для лечения новообразований у млекопитающего, нуждающегося в этом.
2. Применение по п. 1, где опухоль выбрана из группы, состоящей из рака почек, саркомы мягких тканей, рака молочной железы, нейроэндокринной опухоли легких, цервикального рака, рака матки, рака головы и шеи, глиомы, немелкоклеточного рака легких, рака простаты, рака поджелудочной железы, лимфомы, меланомы, мелкоклеточного рака легких, рака яичников, рака толстой кишки, эзофагеального рака, рака желудка, лейкоза, колоректального рака и рака неизвестной первичной локализации.
3. Применение по п.1 или 2, где любой из CCI-779 и интерферона α, либо оба представляются в субтерапевтически эффективных количествах.
4. Применение 42-О-(2-гидрокси)этилрапамицина и интерферона α для получения лекарственного средства для лечения новообразований у млекопитающего, нуждающегося в этом.
5. Применение CCI-779 и интерферона α для получения лекарственного средства для лечения карциномы, положительной на рецептор эстрогена, у млекопитающего, нуждающегося в этом.
6. Применение по п. 5, где положительной на рецептор эстрогена карциномой является рак молочной железы или рак яичников.
7. Применение по п. 5 или 6, где CCI-779 или интерферон α или оба предоставляются в субтерапевтически эффективных количествах.
8. Применение 42-О-(2-гидрокси)этилрапамицина и интерферона α для получения лекарственного средства для лечения карциномы, положительной на рецептор эстрогена, у млекопитающего, нуждающегося в этом.
9. Продукт, содержащий (а) CCI-779, или 42-О-(2-гидрокси)этилрапамицин, и (b) интерферон α, в качестве комбинированного препарата для одновременного, раздельного или последовательного применения при лечении новообразований у млекопитающего, нуждающегося в этом.
10. Применение CCI-779, или 42-О-(2-гидрокси)этилрапамицина, с интерфероном α для изготовления лекарственного средства для лечения новообразований у млекопитающего, нуждающегося в этом.
11. Применение интерферона α с CCI-779, или 42-О-(2-гидрокси)этилрапамицином, для изготовления лекарственного средства для лечения новообразований у млекопитающего.
12. Фармацевтическая упаковка, содержащая лекарственное средство на курс лечения новообразований у одного индивидуального млекопитающего, где упаковка содержит (а) единицы CCI-779 и (b) единицы интерферона α в единичной дозированной форме.
13. Фармацевтическая композиция, применимая при лечении новообразований у млекопитающего, нуждающегося в этом, причем композиция содержит (а) 42-О-(2-гидрокси)этилрапамицин в единичной дозированной форме и (b) единицы интерферона α в комбинации или ассоциации с фармацевтически приемлемым носителем.
14. Комбинация для лечения новообразований, содержащая эффективное для лечения новообразований количество комбинации 42-О-(2-гидрокси)этилрапамицина и интерферона α.
15. Комбинация для лечения новообразований, содержащая эффективное для лечения новообразований количество комбинации CCI-779 и интерферона α.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46449803P | 2003-04-22 | 2003-04-22 | |
| US60/464,498 | 2003-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005136222A true RU2005136222A (ru) | 2006-03-20 |
Family
ID=33310901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005136222/14A RU2005136222A (ru) | 2003-04-22 | 2004-04-14 | Противоопухолевые комбинации |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20040258662A1 (ru) |
| EP (1) | EP1615640B1 (ru) |
| JP (1) | JP2006524246A (ru) |
| KR (1) | KR20060006058A (ru) |
| CN (1) | CN1777424A (ru) |
| AR (1) | AR044039A1 (ru) |
| AT (1) | ATE352301T1 (ru) |
| AU (1) | AU2004231720A1 (ru) |
| BR (1) | BRPI0409632A (ru) |
| CA (1) | CA2519338A1 (ru) |
| CL (1) | CL2004000836A1 (ru) |
| CO (1) | CO5630033A2 (ru) |
| CR (1) | CR7993A (ru) |
| DE (1) | DE602004004520T2 (ru) |
| DK (1) | DK1615640T3 (ru) |
| EC (1) | ECSP056114A (ru) |
| ES (1) | ES2279407T3 (ru) |
| HK (1) | HK1081463A1 (ru) |
| MX (1) | MXPA05010582A (ru) |
| NO (1) | NO20054412L (ru) |
| PL (1) | PL1615640T3 (ru) |
| PT (1) | PT1615640E (ru) |
| RU (1) | RU2005136222A (ru) |
| TW (1) | TW200503753A (ru) |
| UA (1) | UA80756C2 (ru) |
| WO (1) | WO2004093854A2 (ru) |
| ZA (1) | ZA200508574B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2501559C2 (ru) * | 2007-04-10 | 2013-12-20 | Вайет | Противоопухолевая активность ссi-779 при папиллярном раке клеток почечного эпителия |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
| TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
| ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
| AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
| AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
| CN113952338A (zh) * | 2005-02-03 | 2022-01-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| CN102357104B (zh) | 2005-03-07 | 2016-01-27 | 罗巴斯研究机构 | 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用 |
| CA2626326C (en) | 2005-11-04 | 2021-02-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| WO2007056439A1 (en) * | 2005-11-08 | 2007-05-18 | Collegium Pharmaceutical, Inc. | Salts of methylene blue and its derivatives |
| DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
| US20100081681A1 (en) * | 2006-08-16 | 2010-04-01 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| ES2835349T3 (es) | 2008-06-17 | 2021-06-22 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| CN105963313A (zh) | 2008-08-04 | 2016-09-28 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| IL264349B2 (en) | 2009-04-06 | 2024-01-01 | Wyeth Llc | Regimens containing neratinib for the treatment of cancer |
| US9278090B2 (en) * | 2012-09-05 | 2016-03-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preventing the development of mucositis and related disorders |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
| US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US5100899A (en) * | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
| US5080899A (en) * | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5321009A (en) * | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
| ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5286731A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5288711A (en) * | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
| ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5561138A (en) * | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| US5496832A (en) * | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| ATE278421T1 (de) * | 2000-08-11 | 2004-10-15 | Wyeth Corp | Verfahren zur behandlung eines östrogenrezeptor positives karzinoms |
| TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
| TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
| ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| DE60316798T2 (de) * | 2002-06-07 | 2008-07-24 | Waratah Pharmaceuticals, Inc., Toronto | Zusammensetzungen und verfahren zur behandlung von diabetes |
| US20040077677A1 (en) * | 2002-09-17 | 2004-04-22 | Wyeth | Oral formulations |
-
2004
- 2004-04-14 KR KR1020057020106A patent/KR20060006058A/ko not_active Application Discontinuation
- 2004-04-14 JP JP2006510017A patent/JP2006524246A/ja active Pending
- 2004-04-14 PL PL04750108T patent/PL1615640T3/pl unknown
- 2004-04-14 ES ES04750108T patent/ES2279407T3/es not_active Expired - Lifetime
- 2004-04-14 DE DE602004004520T patent/DE602004004520T2/de not_active Expired - Fee Related
- 2004-04-14 TW TW093110355A patent/TW200503753A/zh unknown
- 2004-04-14 EP EP04750108A patent/EP1615640B1/en not_active Expired - Lifetime
- 2004-04-14 BR BRPI0409632-0A patent/BRPI0409632A/pt not_active IP Right Cessation
- 2004-04-14 CA CA002519338A patent/CA2519338A1/en not_active Abandoned
- 2004-04-14 DK DK04750108T patent/DK1615640T3/da active
- 2004-04-14 AU AU2004231720A patent/AU2004231720A1/en not_active Abandoned
- 2004-04-14 AT AT04750108T patent/ATE352301T1/de not_active IP Right Cessation
- 2004-04-14 RU RU2005136222/14A patent/RU2005136222A/ru not_active Application Discontinuation
- 2004-04-14 WO PCT/US2004/011458 patent/WO2004093854A2/en active IP Right Grant
- 2004-04-14 CN CNA2004800105506A patent/CN1777424A/zh active Pending
- 2004-04-14 PT PT04750108T patent/PT1615640E/pt unknown
- 2004-04-14 UA UAA200511006A patent/UA80756C2/uk unknown
- 2004-04-14 MX MXPA05010582A patent/MXPA05010582A/es not_active Application Discontinuation
- 2004-04-14 US US10/823,973 patent/US20040258662A1/en not_active Abandoned
- 2004-04-20 CL CL200400836A patent/CL2004000836A1/es unknown
- 2004-04-21 AR ARP040101342A patent/AR044039A1/es not_active Application Discontinuation
-
2005
- 2005-09-16 CR CR7993A patent/CR7993A/es unknown
- 2005-09-23 NO NO20054412A patent/NO20054412L/no not_active Application Discontinuation
- 2005-10-21 EC EC2005006114A patent/ECSP056114A/es unknown
- 2005-10-21 ZA ZA200508574A patent/ZA200508574B/en unknown
- 2005-11-17 CO CO05116752A patent/CO5630033A2/es not_active Application Discontinuation
-
2006
- 2006-03-28 HK HK06103870A patent/HK1081463A1/xx not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2501559C2 (ru) * | 2007-04-10 | 2013-12-20 | Вайет | Противоопухолевая активность ссi-779 при папиллярном раке клеток почечного эпителия |
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004004520T2 (de) | 2007-11-08 |
| AU2004231720A1 (en) | 2004-11-04 |
| DK1615640T3 (da) | 2007-03-12 |
| DE602004004520D1 (de) | 2007-03-15 |
| MXPA05010582A (es) | 2005-11-23 |
| CO5630033A2 (es) | 2006-04-28 |
| UA80756C2 (en) | 2007-10-25 |
| ECSP056114A (es) | 2006-03-01 |
| JP2006524246A (ja) | 2006-10-26 |
| CL2004000836A1 (es) | 2005-03-04 |
| WO2004093854A3 (en) | 2005-02-03 |
| KR20060006058A (ko) | 2006-01-18 |
| HK1081463A1 (en) | 2006-05-19 |
| ZA200508574B (en) | 2007-04-25 |
| TW200503753A (en) | 2005-02-01 |
| AR044039A1 (es) | 2005-08-24 |
| PT1615640E (pt) | 2007-04-30 |
| WO2004093854A2 (en) | 2004-11-04 |
| NO20054412L (no) | 2005-11-21 |
| BRPI0409632A (pt) | 2006-04-25 |
| CA2519338A1 (en) | 2004-11-04 |
| EP1615640B1 (en) | 2007-01-24 |
| PL1615640T3 (pl) | 2007-05-31 |
| ATE352301T1 (de) | 2007-02-15 |
| EP1615640A2 (en) | 2006-01-18 |
| ES2279407T3 (es) | 2007-08-16 |
| CN1777424A (zh) | 2006-05-24 |
| CR7993A (es) | 2006-05-26 |
| US20040258662A1 (en) | 2004-12-23 |
| NO20054412D0 (no) | 2005-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005136222A (ru) | Противоопухолевые комбинации | |
| JP2006519862A5 (ru) | ||
| JP2006524246A5 (ru) | ||
| IL159859A (en) | Antineoplastic combinations | |
| RU2016122654A (ru) | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка | |
| RU2007126978A (ru) | Комбинации терапевтических агентов для лечения рака | |
| JP2017171685A5 (ru) | ||
| RU2016132759A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| RU2010117635A (ru) | Комбинированная химиотерапия | |
| JP2004525950A5 (ru) | ||
| RU2007134571A (ru) | Комбинация и способы введения терапевтических средств и комбинированной терапии | |
| JP2013126979A5 (ru) | ||
| JP2016535756A5 (ru) | ||
| RU2010138647A (ru) | Комбинированная терапия 238 | |
| IL204987A (en) | A drug containing non-mouse antibody against m – csf and a separate or combined cancer treatment drug | |
| JP2020535173A5 (ru) | ||
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2007136026A (ru) | Варианты ил-21 | |
| Ovejera et al. | Efficacy of 6-Diazo-5-oxo-l-norleucine and N-[N-γ-Glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2008523067A5 (ru) | ||
| JP2021512046A5 (ru) | ||
| JP2004532883A5 (ru) | ||
| RU2020102713A (ru) | Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата | |
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080912 |